Gemeinsamer Bundesausschuss (G-BA)

The Gemeinsamer Bundesausschuss (G-BA), or Federal Joint Committee, is a key decision-making body in the German healthcare system. It determines which medical services and pharmaceuticals are covered by statutory health insurance. The G-BA's decisions directly impact patient access to care and the financial responsibilities of health insurance providers. Recently, the G-BA has been in the news for its decision to allow health insurance companies to reimburse the costs of four medications prescribed for Long Covid, even though these medications are not officially approved for that specific indication (off-label use). This is considered an unusual move, possibly driven by the lack of approved treatments for Long Covid and the urgent need to address the condition. This decision highlights the G-BA's role in navigating complex medical situations and making crucial choices about healthcare coverage in Germany.